The Senate will see you now, Mr. Shkreli.
Senators Claire McCaskill (D-MO) and Susan Collins (R-ME) notified Turing Pharmaceuticals CEO Martin Shkreli of an official U.S. Senate investigation into the skyrocketing price of Daraprim, a
62-year-old drug that saw an overnight price increase of 5,000%.
The letter to Martin Skreli reads:
Mr. Martin Shkreli
Chief Executive Officer
Turing Pharmaceuticals LLC
1177 Avenue of the Americas, 39th Floor
New York City, NY 10036
Dear Mr. Shkreli:
The United States Senate Special Committee on Aging is conducting an investigation into the pricing of off-patent drugs in certain circumstances. We seek your cooperation with this investigation so that the Committee may better understand drug pricing and related regulatory and public policy concerns.
In particular, the Committee wishes to learn more about Turing Pharmaceuticals' recent acquisition of the rights to sell Daraprim, a drug used to treat and prevent infections, from Impax Laboratories and Turing's subsequent decision to increase the price of Daraparim from $13.50 per table to $750.00.
In order to assist us in our investigation, we ask that you provide us with the documents set forth in Schedule A and the information set forth in Schedule B by December 2, 2015. Please submit the material responsive to this request as it becomes available, rather than waiting to provide it all at once. In order to facilitate this production, we request that you schedule a time to meet and confer on the Request from Committee Staff as soon as practicable for you to do so.
There's a 5,000% chance Martin Shkreli's life just got a whole lot more complicated in a hurry. The full letter and the documents can be read
here.